• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by BioAge Labs Inc.

    4/17/25 4:10:03 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BIOA alert in real time by email
    DEFA14A 1 notice_and_access_card_-.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the Securities

    Exchange Act of 1934 (Amendment No. )

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material Pursuant to §240.14a-12

     

    BIOAGE LABS, INC.

    (Name of Registrant as Specified In Its Charter)

    N/A

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

    ☐

    Fee paid previously with preliminary materials

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     


     

    img152400874_0.jpg

    P.O. BOX 8016, CARY, NC 27512-9903 Your vote matters! BioAge Labs, Inc. Annual Meeting of Stockholders Thursday, June 5, 2025 3:30 PM, Eastern Time Annual meeting to be held virtually via the Internet - please visit www.proxydocs.com/BIOA for more details. You must register to attend the meeting online and/or participate at www.proxydocs.com/BIOA For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/BIOA To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 26, 2025. Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting to be Held on June 5, 2025 For Stockholders of Record as of April 10, 2025 To order paper materials, use one of the following methods.. Internet: www.investorelections.com/BIOA Call: 1-866-648-8133 Email: [email protected] * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. SEE REVERSE FOR FULL AGENDA Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved


     

    img152400874_1.jpg

    BioAge Labs, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1 AND 2 PROPOSAL 1. To elect three Class I directors, to serve a three-year term through the third annual meeting of stockholders following this meeting and until a successor has been elected and qualified or until earlier resignation or removal; 1.01 Kristen Fortney, Ph.D. 1.02 Eric Morgen, M.D. 1.03 Vijay Pande, Ph.D. 2. To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ended December 31, 2025. Note: To consider and vote upon such other business as may properly come before the meeting or any adjournment or postponement thereof.


    Get the next $BIOA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIOA

    DatePrice TargetRatingAnalyst
    1/27/2026$73.00Overweight
    Piper Sandler
    12/5/2025$12.00Underweight → Equal-Weight
    Morgan Stanley
    10/22/2025$10.00Neutral → Buy
    Citigroup
    2/28/2025Mkt Perform
    William Blair
    12/10/2024$40.00 → $5.00Overweight → Underweight
    Morgan Stanley
    12/9/2024$42.00 → $7.00Buy → Hold
    Jefferies
    12/9/2024$45.00 → $7.00Buy → Neutral
    Citigroup
    10/21/2024$45.00Buy
    Citigroup
    More analyst ratings

    $BIOA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on BioAge Labs with a new price target

    Piper Sandler initiated coverage of BioAge Labs with a rating of Overweight and set a new price target of $73.00

    1/27/26 8:43:35 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioAge Labs upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded BioAge Labs from Underweight to Equal-Weight and set a new price target of $12.00

    12/5/25 1:35:23 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioAge Labs upgraded by Citigroup with a new price target

    Citigroup upgraded BioAge Labs from Neutral to Buy and set a new price target of $10.00

    10/22/25 7:00:32 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    SEC Filings

    View All

    SEC Form 144 filed by BioAge Labs Inc.

    144 - BioAge Labs, Inc. (0001709941) (Subject)

    2/2/26 9:43:14 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioAge Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BioAge Labs, Inc. (0001709941) (Filer)

    1/22/26 4:34:53 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by BioAge Labs Inc.

    424B5 - BioAge Labs, Inc. (0001709941) (Filer)

    1/22/26 4:32:42 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioAge Announces Pricing of Upsized $115.0 Million Public Offering

    EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the pricing of its upsized underwritten public offering of 5,897,435 shares of its common stock at a price to the public of $19.50 per share. The gross proceeds from this offering are expected to be approximately $115.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by BioAge. The offering is expected to close on or about January 23, 2026, subject to the satisfact

    1/21/26 10:30:00 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioAge Announces Proposed Public Offering

    EMERYVILLE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75.0 million of shares of its common stock. In addition, BioAge intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock. All of the shares of common stock are being offered by BioAge. The proposed offering is subject to mar

    1/20/26 4:01:00 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026

    BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies Growing preclinical and clinical evidence points to central role of the inflammasome in multiple retinal diseases where inflammation is a key feature, including diabetic macular edema (DME) BGE-102 has demonstrated favorable tolerability to date in ongoing Phase 1 trial, with robust reductions in key inflammatory biomarkers including hsCRP, IL-6, and IL-1β Proof-of-concept trial in DME is designed to demonstrate ocular target engagement, supporting future development across inflammation-driven retinal diseases DME tri

    1/20/26 9:00:00 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Rubin Paul D exercised 7,433 shares at a strike of $4.77 and sold $139,369 worth of shares (7,433 units at $18.75) (SEC Form 4)

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    2/3/26 4:26:11 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Goldstein Dov A Md exercised 3,541 shares at a strike of $4.38, increasing direct ownership by 14% to 29,491 units (SEC Form 4)

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    2/3/26 4:23:00 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Goldstein Dov A Md exercised 3,542 shares at a strike of $4.38, increasing direct ownership by 16% to 25,950 units (SEC Form 4)

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    1/21/26 4:20:56 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Hemrajani Rekha bought $54,000 worth of shares (3,000 units at $18.00) (SEC Form 4)

    4/A - BioAge Labs, Inc. (0001709941) (Issuer)

    3/10/25 4:11:28 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Principal Accounting Officer Barton Shane bought $47,376 worth of shares (2,632 units at $18.00) (SEC Form 4)

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    3/10/25 4:10:37 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Pande Vijay Satyanand bought $4,329,019 worth of shares (219,195 units at $19.75) (SEC Form 4)

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    10/3/24 7:19:49 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by BioAge Labs Inc.

    SC 13G - BioAge Labs, Inc. (0001709941) (Subject)

    11/14/24 4:15:56 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by BioAge Labs Inc.

    SC 13G - BioAge Labs, Inc. (0001709941) (Subject)

    11/12/24 4:15:53 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by BioAge Labs Inc.

    SC 13D - BioAge Labs, Inc. (0001709941) (Subject)

    10/4/24 8:21:35 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care